Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
SAN DIEGO, Nov. 01, 2016 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it will report its third quarter 2016 financial and operating results after the close of U.S. financial markets on Tuesday, November 8, 2016. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.
| Conference call and webcast: | |
| Date: | November 8, 2016 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
| Passcode: | 10003680 |
| Via web: | www.traconpharma.com; “Events and Presentation” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550-0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
